Showing 9 articles tagged 'Biomarkers':
Researchers at the Institute of Cancer Research have created a powerful new three-in-one blood test, which could help doctors monitor whether a treatment is working and how a man's cancer is responding. We examine the results and find out why it's another step in the creation of targeted treatments for prostate cancer.
Our £1.5m of Movember Foundation Translational Awards will ensure four groundbreaking projects make it through the labs and into clinical trials.
BLOG: Despite a misleading Telegraph article, the science of biomarkers is still well worth getting excited about, says Sophie Lutter.
BLOG: Sophie Lutter explores the ins and outs of genetic testing for prostate cancer, and what it might mean for men and their families, in terms of improving treatment and identifying those at risk.
BLOG: Earlier this month the UK’s biggest gathering of cancer experts took place in Liverpool – the NCRI cancer conference. We sponsored a session and went along to represent the organisation, meet experts and hear from the cutting edge of cancer research. But we also wanted to find out what other prostate cancer experts made of it.
Scientists now have a better understanding of the inherited risk of prostate cancer, after an international study identified 23 new genetic variants (changes in the DNA sequence) associated with increased risk of the disease.
PRESS COMMENT: Screening men with a family history of prostate cancer for a range of gene mutations can identify those who are at high risk of aggressive forms of the disease and in need of lifelong monitoring, a new study has shown.
Prostate Cancer UK funded scientists at Newcastle University have found a new trick that prostate cancer cells use to escape from the body’s usual methods of controlling cell growth. This may help to explain why some treatments don’t work as well as expected.
Recently published research brings us a step closer to finding a solution to the problem of hormone resistance in prostate cancer.